Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Transplant Issues

Delayed lymphocyte infusion in children given SCT

Bone Marrow Transplantation volume 41, pages S23–S26 (2008)Cite this article

Abstract

The use of DLI can change chimerism and prevent rejection and relapse. However, the prerequisite for a successful use of this powerful and potentially harmful tool is a minimal burden with resting leukemia or in the case of nonmalignant disease autologous cells. Therefore, a monitoring of the hematopoietic chimerism and of the post-transplant MRD is recommended with a narrow (best: weekly) time schedule. Also, using low and increasing numbers of DLI, a GvHD can be avoided or even minimized.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  Google Scholar 

  2. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  Google Scholar 

  3. Riddell SR, Murata M, Bryant S, Warren EH . T-cell therapy of leukemia. Cancer Control 2002; 9: 114–122.

    Article  Google Scholar 

  4. Bader P, Holle W, Klingebiel T, Handgretinger R, Benda N, Schlegel PG et al. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1997; 19: 697–702.

    Article  CAS  Google Scholar 

  5. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999; 13: 2079–2086.

    Article  CAS  Google Scholar 

  6. Bader P, Beck J, Schlegel PG, Handgretinger R, Niethammer D, Klingebiel T . Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse? Bone Marrow Transplant 1997; 20: 79–81.

    Article  CAS  Google Scholar 

  7. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1705.

    Article  Google Scholar 

  8. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T . How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35: 107–119.

    Article  CAS  Google Scholar 

  9. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004; 33: 815–821.

    Article  CAS  Google Scholar 

  10. Yoshimi A, Bader P, Matthes-Martin S, Stary J, Sedlacek P, Duffner U et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005; 19: 971–977.

    Article  CAS  Google Scholar 

  11. Willasch A, Hoelle W, Kreyenberg H, Niethammer D, Handgretinger R, Lang P et al. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica 2006; 91: 788–794.

    PubMed  Google Scholar 

  12. Hoelle W, Beck JF, Dueckers G, Kreyenberg H, Lang P, Gruhn B et al. Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia. Bone Marrow Transplant 2004; 33: 219–223.

    Article  CAS  Google Scholar 

  13. Krejci O, van der Velden VH, Bader P, Kreyenberg H, Goulden N, Hancock J et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003; 32: 849–851.

    Article  CAS  Google Scholar 

  14. Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 24–29.

    Article  Google Scholar 

  15. Bader P, Hancock J, Kreyenberg H, Goulden NJ, Niethammer D, Oakhill A et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16: 1668–1672.

    Article  CAS  Google Scholar 

  16. Szczepanski T . Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007; 21: 622–626.

    Article  CAS  Google Scholar 

  17. Schilham MW, Balduzzi A, Bader P . Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplant 2005; 35 (Suppl 1): S49–S52.

    Article  Google Scholar 

  18. Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH . Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev 2005; 19: 289–300.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Pediatric Hematology and Oncology, Zentrum für Kinder- und Jugendmedizin, Klinik III, Johann Wolfgang Goethe University, Frankfurt/Main, Germany

    T Klingebiel & P Bader

Authors
  1. T Klingebiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Bader
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the EBMT Paediatric Working Party

Corresponding author

Correspondence to T Klingebiel.

Additional information

Conflict of interest

Neither of the authors declared any financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klingebiel, T., Bader, P. & on behalf of the EBMT Paediatric Working Party. Delayed lymphocyte infusion in children given SCT. Bone Marrow Transplant 41 (Suppl 2), S23–S26 (2008). https://doi.org/10.1038/bmt.2008.49

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.49

Keywords

This article is cited by

Search

Advanced search

Quick links